Tecastemizole

Drug Profile

Tecastemizole

Alternative Names: Norastemizole; R 41232; Soltara

Latest Information Update: 03 Dec 2003

Price : $50

At a glance

  • Originator Sepracor
  • Developer Janssen L.P.; Sepracor
  • Class Antiallergics; Nonsedating antihistamines
  • Mechanism of Action Histamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 03 Dec 2003 Discontinued - Preregistration for Seasonal allergic rhinitis in USA (PO)
  • 03 Dec 2003 Discontinued - Preregistration for Perennial allergic rhinitis in USA (PO)
  • 08 May 2002 A clinical study has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top